Deutsche Bank
ANTX icon

Deutsche Bank’s AN2 Therapeutics ANTX Stock Holding History

Deutsche Bank’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-39,472
Closed -$809K – 3613
2023
Q4 		$809K Buy
+39,472
New +$660K ﹤0.01% 2132
2023
Q2 		– Sell
-6,815
Closed -$67.3K – 3809
2023
Q1 		$67.3K Buy
6,815
+2,026
+42% +$22.5K ﹤0.01% 3474
2022
Q4 		$45.6K Buy
4,789
+2,903
+154% +$38.9K ﹤0.01% 3602
2022
Q3 		$33K Sell
1,886
-310
-14% -$3.61K ﹤0.01% 3684
2022
Q2 		$17K Buy
+2,196
New +$29.1K ﹤0.01% 3954

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank's ANTX Position: Q1 2024 in Review

Deutsche Bank sold out of AN2 Therapeutics (ANTX) in Q1 2024, closing a stake of 39,472 shares — an estimated $809K sold.

Deutsche Bank first reported a position in ANTX in Q2 2022 and held it in 5 quarters. The position peaked at $809K in Q4 2023. 54 funds tracked by Wall St. Rank hold ANTX as of Q1 2024.

  • Deutsche Bank reported no remaining AN2 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Deutsche Bank sold 39,472 AN2 Therapeutics shares in Q1 2024, an estimated $809K.
  • Deutsche Bank first reported a position in AN2 Therapeutics in Q2 2022 and held it in 5 quarters.
  • Deutsche Bank's AN2 Therapeutics position peaked at $809K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2024.

Based on Deutsche Bank's 13F filing for Q1 2024, filed 15 May 2024.